Skip to content

JBIO JBIO Other Income (Expense)

Other Income (Expense) at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$193K-87.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
$4.1M-25.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$18.21M-55.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$1.28M-16.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$62K+27.1%
Vor Biopharma logo
Vor BiopharmaVOR
-$184.43M-23,010%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's other income (expense)?
JBIO (JBIO) reported other income (expense) of $3.09M in Q1 2026.
How has JBIO's other income (expense) changed year-over-year?
JBIO's other income (expense) increased by 120.9% year-over-year, from -$14.79M to $3.09M.
What is the long-term trend for JBIO's other income (expense)?
Over 3 years (2021 to 2024), JBIO's other income (expense) has grown at a 467.3% compound annual growth rate (CAGR), from $62K to -$11.32M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.